Understanding how lncRNAs affect multiple myeloma biology and treatment
Official title: Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
Funded at Dana-Farber Cancer Inst · NIH-11403925 · Data updated 2026-11-12
This grant studies how long noncoding RNAs influence multiple myeloma behavior and response to therapy using bone marrow models.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $315,950 |
| NIH project number | 5P01CA155258-14 |
| Project ID | NIH-11403925 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma or individuals with related bone marrow abnormalities who may benefit from future RNA-targeted therapies.
✕Less likely to help
Patients without multiple myeloma or related bone marrow conditions may not benefit from this basic research.
What this research studies
Researchers at Dana-Farber are exploring how lncRNAs shape the growth, survival, and drug resistance of myeloma cells in the bone marrow. They combine genomic analyses with in vitro and in vivo models to identify RNA-driven regulatory networks and test targeted therapies. The work aims to uncover new molecular mechanisms that could lead to better, more durable treatments for people living with multiple myeloma. This project builds on previous findings that certain lncRNAs are linked to patient outcomes and could guide future therapeutic strategies.
Why it matters
Potential benefit: It could reveal new RNA-related targets and therapies to improve survival and quality of life for people with multiple myeloma.
How similar studies have gone: Previous studies have shown that lncRNA patterns can predict outcomes and influence myeloma biology, supporting potential translational value.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Fulciniti, Mariateresa — Dana-Farber Cancer Inst
- Study coordinator: Fulciniti, Mariateresa
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.